Skip to NavigationSkip to content

NICE to review its decision making processes

Published on 22/07/19 at 11:09am

Britain’s cost-effectiveness body NICE has said it will review the methods it uses to develop guidance on drugs, medical devices, and diagnostics.

The review will see NICE look at the processes through which its decisions are made. This will include looking at the way data analytics and real-world evidence can be used in the decision making process. Proposals will be presented for public consultation in the summer of 2020.  

Sir Andrew Dillon, chief executive of NICE, commented: “This update is part of the regular review and refresh of our methods to ensure that they are robust and up-to-date.

“NICE is undertaking this review at a time of unprecedented change in the healthcare system, where developments such as personalised medicine, digitalisation of health, and use of cell and gene therapy, mean products are becoming ever more challenging to evaluate.

“Keeping NICE’s methods up to date is an important contribution to managing these changes. The expanded Accelerated Access Collaboration, and the development of NHS England’s commercial framework are other important elements.

“NICE encourages people who are interested in the methods and process review to register an interest on the NICE website to ensure they receive regular updates on this work.”

Other topics scheduled for consideration include: the ways in which quality of life is factored in to economic analyses and issues related specifically to technology.

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches